Program
MBS314 for Injection
A development code.
Its studies are mostly in Multiple Myeloma, led by Beijing Mabworks Biotech.
Furthest: phase 2, since Oct 28, 20261 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Mabworks Biotech | 11 open or running | phase 2since Oct 28, 2026 | Oct 28, 2026 | Dec 2027phase 2 · NCT07911748 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 28, 2026First study: phase 2 study in Multiple MyelomaFirst studyNCT07911748 · 78 planned
Ahead
- Dec 2027Primary completion: phase 2 study in Multiple MyelomaNCT07911748
TargetBeta
“This is a Phase I/II, multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of MBS314, a novel asymmetric trivalent trispecific humanized antibody targeting GPRC5D, BCMA and CD3, a…”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| QLS4131rule | Qilu Pharmaceutical | phase 3 | 3 |
| QLS32015rule | Qilu Pharmaceutical | phase 3 | 2 |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| TQB2029 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07911748Multiple Myeloma | 2 | Not yet recruiting | Dec 2027 | 78 |
How it is read
Names in the registry
- “MBS314 for Injection”, 1 entry
Codes read as this program: MBS314.
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.